Boehringer Ingelheim GmbH
http://www.boehringer-ingelheim.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Boehringer Ingelheim GmbH
Beckley Psytech Takes Another Step Toward Psychedelic Antidepressants
The private British biotech announced positive results from its Phase IIa study of BPL-003, which it said support its Phase IIb study of the same DMT-based drug.
DTx And Drug Deal Sees Closed Loop Medicine And Teva Team Up On Precision Care
Medicines are still typically prescribed based on average effects in a population and rarely dose-optimized for the individual, says Closed Loop Medicine. The company sees a new strategic partnership with Teva UK as another step in advancing personalized medicine.
Proposed US BIOSECURE Act - Do Lonza, Other CDMOs Gain And How Soon?
Concerns over the impact of the proposed US BIOSECURE Act on the CRO and CDMO segments linger despite proponent Mike Gallagher’s plan to leave Congress soon. Which global manufacturers could gain, what determines a shift away from Chinese companies and how imminent is this? Scrip brings insights from industry feedback and other sources.
China Biotech IPO Drought Lingers But HK Sees First Of 2024
Biotech IPOs on the Chinese mainland have dried up since June 2023 due to regulatory tightening, but Hong Kong is still open to listings of pre-revenue ventures and has seen its first offering of this year.
Company Information
- Industry
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Abexxa Biologics Inc
- AMAL Therapeutics SA
- ICD Therapeutics
- NBE Therapeutics AG
- SSP Co., Ltd.
- Vira Therapeutics GmbH (Vira T)
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice